Article 65. Suspension of Medicinal Product

When obtaining information on cases of side effects, which are not specified in the Package Leaflet for a medicinal product, serious adverse reactions and unexpected adverse reactions that have occurred when administering medicinal products, on particularities of its interaction with other medicinal products, which may constitute a threat to the life or health of patients, as well as information inconsistent with the information on the medicinal product contained in the Package Leaflet, the authorized federal executive body shall consider the question of possible suspension of that medicinal product in the order established by the authorized federal executive body.